intravenous glutathione randomized controlled trial parkinson's disease Phase 1/2a clinical of hESC-derived dopamine progenitors in disease: Cell Targeting Ferroptosis in Parkinson's Disease:
Description
Cells were treated in 100 L of media
GNPIPP12MA is an FTO inhibitor-loaded GSH-bioimprinted nanocomposite (69)
As a next step, the reader measured continuously for 6 min the fluorescence intensity at 410 and 470 nm (510 nm of emission) of each well to determine the cytoplasmic pH before treatment
References Guangyan, Y
